Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-03-27
1999-02-16
Higel, Floyd D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514256, 544295, 544370, 546193, 546194, 546210, 5462727, 5483355, A61K 3144, C07D21168, C07D21180, C07D21302
Patent
active
058721363
ABSTRACT:
The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
REFERENCES:
patent: 3691178 (1972-09-01), Baldwin et al.
patent: 5159083 (1992-10-01), Thurkauf et al.
patent: 5428164 (1995-06-01), Thurkauf et al.
patent: 5559137 (1996-09-01), Adams et al.
patent: 5616601 (1997-04-01), Khanna et al.
patent: 5633376 (1997-05-01), Thurkauf et al.
patent: 5646280 (1997-07-01), Thurkauf et al.
patent: 5656762 (1997-08-01), Thurkauf et al.
Anthony Neville J.
Gomez Robert P.
Graham Samuel L.
Daniel Mark R.
Higel Floyd D.
Merck & Co. , Inc.
Muthard David A.
LandOfFree
Arylheteroaryl inhibitors of farnesyl-protein transferase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylheteroaryl inhibitors of farnesyl-protein transferase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylheteroaryl inhibitors of farnesyl-protein transferase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2062757